Correlation Between Par Drugs and Kilitch Drugs
Specify exactly 2 symbols:
By analyzing existing cross correlation between Par Drugs And and Kilitch Drugs Limited, you can compare the effects of market volatilities on Par Drugs and Kilitch Drugs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Par Drugs with a short position of Kilitch Drugs. Check out your portfolio center. Please also check ongoing floating volatility patterns of Par Drugs and Kilitch Drugs.
Diversification Opportunities for Par Drugs and Kilitch Drugs
-0.58 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Par and Kilitch is -0.58. Overlapping area represents the amount of risk that can be diversified away by holding Par Drugs And and Kilitch Drugs Limited in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Kilitch Drugs Limited and Par Drugs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Par Drugs And are associated (or correlated) with Kilitch Drugs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Kilitch Drugs Limited has no effect on the direction of Par Drugs i.e., Par Drugs and Kilitch Drugs go up and down completely randomly.
Pair Corralation between Par Drugs and Kilitch Drugs
Assuming the 90 days trading horizon Par Drugs And is expected to generate 1.48 times more return on investment than Kilitch Drugs. However, Par Drugs is 1.48 times more volatile than Kilitch Drugs Limited. It trades about 0.08 of its potential returns per unit of risk. Kilitch Drugs Limited is currently generating about -0.01 per unit of risk. If you would invest 24,650 in Par Drugs And on September 3, 2024 and sell it today you would earn a total of 4,390 from holding Par Drugs And or generate 17.81% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Par Drugs And vs. Kilitch Drugs Limited
Performance |
Timeline |
Par Drugs And |
Kilitch Drugs Limited |
Par Drugs and Kilitch Drugs Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Par Drugs and Kilitch Drugs
The main advantage of trading using opposite Par Drugs and Kilitch Drugs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Par Drugs position performs unexpectedly, Kilitch Drugs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kilitch Drugs will offset losses from the drop in Kilitch Drugs' long position.Par Drugs vs. Elgi Rubber | Par Drugs vs. Allied Blenders Distillers | Par Drugs vs. Sarveshwar Foods Limited | Par Drugs vs. Modi Rubber Limited |
Kilitch Drugs vs. Life Insurance | Kilitch Drugs vs. Power Finance | Kilitch Drugs vs. HDFC Bank Limited | Kilitch Drugs vs. State Bank of |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Valuation Check real value of public entities based on technical and fundamental data |